Home > Blog Tag

Blog Posts by Tag: Molecular

No Surprises Act: Your Top Questions Answered - Part 1

The No Surprises Act (NSA), which went into effect on January 1, has many providers scrambling. The No Surprises Act provided protections for patients who unknowingly receive care from an out-of-network provider by addressing surprise billing and banning balance billing. Implementing the requirements of the No Surprises Act will require a new level of coordination between providers, payors, and...

Read


Integrating Informatics for Clinical-Genomic Collaboration and Analysis

I recently had the pleasure of co-authoring an article in Oncology Practice Management. The article, titled “An Integrated Informatics Approach for Clinical-Genomic Knowledge Sharing and Analysis” outlines the design of a real-time registry that aggregates heterogeneous clinical and genomic data (along with other molecular results) in a unified structure to identify, vet, and fulfill...

Read


Preparing for the No Surprises Act: Learn How Your Billing Solution Can Help

Effective January 1, 2022, the No Surprises Act (NSA) established new federal protections against surprise medical bills and balance billing for services received from out-of-network providers. The Act applies to emergency and non-emergency services provided by all healthcare providers and all commercial health plans. The No Surprises Act is not applicable to Medicare and Medicaid programs,...

Read


XIFIN Acquisition Opens Opportunities for Diagnostics Providers, Targets Patient-Centric Care

XIFIN recently announced the acquisition of OmniSYS, a healthcare technology company that serves more than 30,000 pharmacies, including four out of the top five national chains. OmniSYS capabilities include patient engagement, medical claims processing, automated pricing, managing clinical workflow, and supporting new clinical services such as immunizations, medication management, point-of-care...

Read


How Precision Medicine and Data Analytics Impact the Journey of Patients with Cancer

Earlier this year, I had the pleasure of co-authoring an article in Oncology Practice Management with Randy Erickson, RN, MBA, Chief Executive Officer of Utah Cancer Specialists and Linh Mekuria, MPA, clinical informaticist with XIFIN, Inc. The article, titled “The Intersection of Precision Medicine and Data Analysis in the Community Oncology Setting” explores the role of precision medicine and...

Read


4 Ways to Maximize Revenue Regarding Genetic Testing

As genetic testing has continued to increase, reimbursements on genetic test claims remain a significant challenge for clinical laboratories and anatomic pathology groups.According to Concert Genetics, the number of total genetic tests in 2012 was 10,000. By year-end 2020, that number had grown to 166,450 tests. Not only is the number of tests increasing, but the testing is becoming more...

Read


UHC Implements DEX Z-Code Requirements on Medicare Advantage Claims Starting June 1, 2021

this post was updated on June 1, 2021. In March 2021, United Healthcare announced an updated policy for Medicare Advantage plans, whereas they will be requiring providers to include the appropriate DEX Z-Code identifier on claims beginning June 1, 2021. United Healthcare has announced this policy update has been delayed and will not be implemented on June 1, 2021. Further communication will be...

Read


After Large Spikes in 2020, Diagnostic Laboratory Testing Volumes on the Decline

As XIFIN CEO Lâle White wrote in her recent LinkedIn article, the COVID-19 pandemic created many challenges for the diagnostic industry in 2020. In the preceding years, many laboratories were running lean with little excess capacity. With the surge in COVID-19 testing demand, labs had to quickly add capacity to handle the new testing volume. In addition, dynamic regulatory changes designed to...

Read